Our basic research looks at the mechanisms underlying lymphomagenesis for both B- and T-cell lymphomas. Using profiling of gene and microRNA expression as well as detection of gene mutation, we are interested to determine the predominant signalling pathways which, when dysregulated, can lead to unbridled cell growth and/or resistance to therapy. We are also interested to study the effect of Epstein Barr Virus (EBV) on the lymphogenesis process in EBV-positive lymphomas such as natural killer/T-cell lymphomas (NKTL). These avenues of research will help us improve the clinical application of several emerging therapeutic strategies, including those that target the immune system.​​

For translational research, we are partnering with local start-ups to develop diagnostic and/or prognostic assays to differentiate patients with reactive lymph node versus those with lymphomas, as well as for more accurate subtyping of lymphomas so as to facilitate downstream therapeutic decisions. We are also working towards digitising the diagnosis of lymphomas by partnering with local start-ups to develop artificial intelligence algorithms on whole slide images from patient biopsies. Through this endeavour, we hope to work towards automation of the tedious and boring aspects of pathology to free up pathologists’ time for more difficult interpretations of lymphoma cases.